<SEC-DOCUMENT>0001263312-26-000003.txt : 20260325
<SEC-HEADER>0001263312-26-000003.hdr.sgml : 20260325
<ACCEPTANCE-DATETIME>20260325184639
ACCESSION NUMBER:		0001263312-26-000003
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20260323
FILED AS OF DATE:		20260325
DATE AS OF CHANGE:		20260325

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			ORVILLE JACOB A
		CENTRAL INDEX KEY:			0001263312
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-02189
		FILM NUMBER:		26793897

	MAIL ADDRESS:	
		STREET 1:		5505 ENDEAVOR LANE
		CITY:			MADISON
		STATE:			WI
		ZIP:			53719

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABBOTT LABORATORIES
		CENTRAL INDEX KEY:			0000001800
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				360698440
		STATE OF INCORPORATION:			IL
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		100 ABBOTT PARK ROAD
		CITY:			ABBOTT PARK
		STATE:			IL
		ZIP:			60064-3500
		BUSINESS PHONE:		2246676100

	MAIL ADDRESS:	
		STREET 1:		100 ABBOTT PARK ROAD
		CITY:			ABBOTT PARK
		STATE:			IL
		ZIP:			60064-3500
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>form3-03252026_100333.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0607</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2026-03-23</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0000001800</issuerCik>
        <issuerName>ABBOTT LABORATORIES</issuerName>
        <issuerTradingSymbol>ABT</issuerTradingSymbol>
        <issuerForeignTradingSymbol></issuerForeignTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001263312</rptOwnerCik>
            <rptOwnerName>ORVILLE JACOB A</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerNonUSAddressFlag>false</rptOwnerNonUSAddressFlag>
            <rptOwnerStreet1>100 ABBOTT PARK ROAD</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>ABBOTT PARK</rptOwnerCity>
            <rptOwnerState>IL</rptOwnerState>
            <rptOwnerZipCode>60064</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>false</isDirector>
            <isOfficer>true</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle>Senior Vice President</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common shares without par value</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>37238</value>
                    <footnoteId id="F1"/>
                    <footnoteId id="F2"/>
                    <footnoteId id="F3"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable></derivativeTable>

    <footnotes>
        <footnote id="F1">On March 23, 2026, Abbott Laboratories (&quot;Abbott&quot;) acquired Exact Sciences Corporation (&quot;Exact&quot;) pursuant to the Agreement and Plan of Merger, dated as of November 19, 2025 (the &quot;Merger Agreement&quot;), by and among Abbott, Exact and Badger Merger Sub I, Inc. (&quot;Merger Sub&quot;).  Pursuant to the terms of, and subject to the conditions contained in, the Merger Agreement, Merger Sub merged with and into Exact, with Exact surviving as a direct, wholly owned subsidiary of Abbott (the &quot;Merger&quot;). At the effective time of the Merger (the &quot;Effective Time&quot;), each share of common stock, par value $0.01 per share, of Exact (&quot;Exact common stock&quot;) issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was automatically converted into the right to receive $105.00 in cash, without interest, less any applicable withholding taxes (the &quot;Merger Consideration&quot;).</footnote>
        <footnote id="F2">Further, each restricted stock unit award granted under an Exact stock plan (each, an &quot;RSU&quot;) on or after November 19, 2025, other than RSU awards granted to Exact's non-employee directors, was assumed by Abbott at the Effective Time as an Abbott restricted stock unit award on substantially the same terms and conditions as were applicable to the corresponding RSU award (including with respect to double-trigger vesting protections), with the number of Abbott common shares underlying such Abbott restricted stock unit award determined based on the Merger Consideration divided by the average closing price of an Abbott common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time.</footnote>
        <footnote id="F3">These shares represent a restricted stock unit award that has a 4-year term, with 1/4 of the award vesting each year, beginning on February 25, 2027. The award includes the right to have shares withheld for tax purposes.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Jacob A. Orville by Jessica H. Paik, Attorney-in-Fact</signatureName>
        <signatureDate>2026-03-25</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>ex24-03252026_100342.htm
<TEXT>
<!DOCTYPE html PUBLIC "-//IETF//DTD HTML//EN">
<html><head><title>32L Timeline</title><meta name="author" content="Abbott Laboratories"><meta name="date" content="03/16/2026"></head><body style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<p style="margin:0px" align="center"><br></p>
<p style="margin:0px; font-size:11pt" align="center"><b><u>POWER OF ATTORNEY</u></b></p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin:0px; text-indent:48px; font-size:11pt">The undersigned constitutes and appoints ELIZABETH C. CUSHMAN, JESSICA H. PAIK, and AARON N. RICE, and each of them individually, as the undersigned&#146;s true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for the undersigned and in the undersigned&#146;s name, place and stead, and in the undersigned&#146;s capacity as an officer of Abbott Laboratories, an Illinois corporation (the &#147;Company&#148;), (i) to prepare, sign, and file with the Securities and Exchange Commission (&#147;SEC&#148;) any and all forms and documents required under federal securities laws, including Rule 144 of the Securities Act of 1933, as amended, and Section 16(a) of the Securities Exchange Act of 1934, as amended, a Form ID and any other documents necessary to obtain codes, passphrases and passwords necessary to make electronic filings with the SEC, and any other documents in connection therewith, and (ii) to enroll the undersigned and serve as an account administrator for the undersigned&#146;s account in the SEC&#146;s enhanced Electronic Data Gathering, Analysis, and Retrieval system (&#147;EDGAR Next&#148;) and take any action that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned pursuant to the authority granted to such attorney-in-fact as an account administrator for the undersigned&#146;s account in EDGAR Next, in each case, granting unto said attorney-in-fact and agent full power and authority to do and perform each act and thing requisite, necessary or desirable to be done under said Rule 144 and Section 16(a) and pursuant to such attorney-in-fact&#146;s and agent&#146;s authority as an account administrator for the undersigned&#146;s account in EDGAR Next, as fully for all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent may lawfully do or cause to be done by virtue hereof.</p>
<p style="margin:0px"><br></p>
<p style="margin:0px; text-indent:48px; font-size:11pt">A copy of this power of attorney shall be filed with the SEC. &nbsp;The authorization set forth above shall continue in full force and effect until the undersigned is no longer required to make filings under Rule 144 and Section 16(a) with respect to the Company or if earlier, until the undersigned revokes such authorization by written instructions to the attorney-in-fact.</p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin:0px; font-size:11pt">Date: March 13, 2026</p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin:0px; padding-left:336px; font-size:11pt"><u>/s/ Jacob A. Orville</u></p>
<p style="margin:0px; padding-left:336px; font-size:11pt">Signature of Reporting Person</p>
<p style="margin:0px"><br></p>
<p style="margin:0px; padding-left:336px; font-size:11pt">Jacob A. Orville</p>
<p style="margin:0px; padding-left:336px; font-size:11pt">Abbott Laboratories</p>
<p style="margin:0px; padding-left:336px; font-size:11pt">100 Abbott Park Road</p>
<p style="margin:0px; padding-left:336px; font-size:11pt">Abbott Park, IL 60064</p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br><br><br></p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
</body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
